Search results
Results from the WOW.Com Content Network
A newly minted biopharma initial public offering (IPO) has Wall Street analysts rushing to the gates to price it for massive gains.. Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its ...
The IPO and subsequent stock sales raised hundreds of millions of dollars, but little of the money went toward additional trials on Zolgensma, an analysis by KEI, the public advocacy group, concluded.
For premium support please call: 800-290-4726 more ways to reach us
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies.
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.
The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2] In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. [3]
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need.